Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 69Fallopian Tube Neoplasms 18Endometrial Neoplasms 8Carcinoma, Ovarian Epithelial 8Breast Neoplasms 7Neoplasms 5Pancreatic Neoplasms 3Cystadenocarcinoma, Serous 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Prostatic Neoplasms 2Ovarian Diseases 2Neoplasm Metastasis 2Gonadal Disorders 2Genital Neoplasms, Female 2Genital Diseases, Female 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Carcinoma 2Adnexal Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Sarcoma 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1Recurrence 1Prostatic Diseases 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Platinum-resistant Ovarian Cancer 1

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Doxorubicin 2niraparib 1copanlisib 1Standard of Care 1Saline Solution 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Lidocaine 1Gemcitabine 1Conservative Treatment 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × niraparib × Gynecologic × Clear all
NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡